Madison's EnsoData secures growth capital from CIBC Innovation Banking

EnsoData, a Madison-based healthtech company building AI-powered software in Wisconsin for sleep care, has secured growth capital financing from CIBC Innovation Banking. The size and terms were not disclosed.

EnsoData's flagship product, EnsoHST, is a multi-night home sleep testing solution that pairs a wearable device with a mobile app. The company says the system automates analysis and removes operational friction for clinicians, with the goal of accelerating diagnosis and expanding capacity in sleep care. Its software is FDA-cleared.

"This facility from CIBC Innovation Banking enables EnsoData to expand access to the sleep care pathway today, while accelerating our investment in AI-driven innovations that will shape the future of diagnostics across multiple clinical domains," said Matt Dobereiner, CFO of EnsoData.

According to the company, its technology has supported the care of more than 2.9 million patients to date. EnsoData also says it is exploring applications in additional clinical areas beyond sleep, though specifics were not provided.

CIBC Innovation Banking, which manages over $11 billion across tech and life sciences and says it has worked with more than 700 venture- and private equity-backed businesses, operates from 14 offices in the U.S., Canada and the U.K., including an office in Chicago.

"CIBC Innovation Banking is very glad to support EnsoData's growth and continued adoption among sleep medicine professionals," said Andrew Schwartz, Managing Director at CIBC Innovation Banking, adding that the company “is at the exciting intersection of leveraging AI and machine-learning technology to improve access for patients to the care pathway."

How the capital will be allocated between scaling EnsoHST and the company's planned expansion into other clinical areas was not detailed in the announcement.

‍